Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01430312 · ClinicalTrials.gov registry record · Phase 1
21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation
A Phase 1 study of Healthy, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01430312: Completed Phase 1 study of Healthy, sponsored by LEO Pharma.
NCT01430312 is a Phase 1 study of Healthy that has completed, run by LEO Pharma. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01430312, a Phase 1 study of Healthy, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the irritancy potential of azelaic acid pre-foam formulation.
Primary Outcome
skin reaction as well as superficial layer effects will be scored according to standardized scales
Conditions Studied
Interventions
- DRUG azelaic acid pre-foam formulation
- DRUG Vehicle pre-foam formulation
- DRUG Water
- DRUG Sodium lauryl sulfate
Study Locations (1)
North Dakota
- Robert I. Cooper, MD - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT01430312 record still lists
NCT01430312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which azelaic acid pre-foam formulation is the first listed.
NCT01430312 reports a single indexed study location in North Dakota.
Frequently Asked Questions
What is clinical trial NCT01430312 about?
NCT01430312 is a clinical study titled "21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation". The purpose of this study is to determine the irritancy potential of azelaic acid pre-foam formulation.
What is the current status of trial NCT01430312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-09. Estimated completion is 2011-12.
What conditions does trial NCT01430312 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01430312?
The interventions under investigation include: azelaic acid pre-foam formulation (DRUG), Vehicle pre-foam formulation (DRUG), Water (DRUG), Sodium lauryl sulfate (DRUG).
Who is sponsoring clinical trial NCT01430312?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01430312 being conducted?
This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01430312's enrollment target sits among peer trials
40 540th of 1090 higher than 513 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia